NASDAQ:MTFB - Nasdaq -
0.105
-0.01 (-4.63%)
The current stock price of MTFB is 0.105 null. In the past month the price decreased by -33.92%. In the past year, price decreased by -98.25%.
Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company's product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK.
Motif Bio Plc
201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE
LONDON X0 EC4Y0DT
CEO: Graham George Lumsden
Phone: 212-210-6248
The current stock price of MTFB is 0.105 null. The price decreased by -4.63% in the last trading session.
The exchange symbol of Motif Bio Plc is MTFB and it is listed on the Nasdaq exchange.
MTFB stock is listed on the Nasdaq exchange.
Motif Bio Plc (MTFB) has a market capitalization of 1.56M null. This makes MTFB a Nano Cap stock.
Motif Bio Plc (MTFB) has a resistance level at 0.12. Check the full technical report for a detailed analysis of MTFB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MTFB does not pay a dividend.
Motif Bio Plc (MTFB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.07).
ChartMill assigns a fundamental rating of 1 / 10 to MTFB. MTFB has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months MTFB reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 63.16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -570.58% | ||
ROE | N/A | ||
Debt/Equity | -0.37 |
ChartMill assigns a Buy % Consensus number of 80% to MTFB. The Buy consensus is the average rating of analysts ratings from 2 analysts.